3 Stocks Sinking on Downgrades

Options traders have been betting against PTCT stock in recent weeks

Managing Editor
Oct 9, 2017 at 10:02 AM
facebook X logo linkedin

Analysts are weighing in on healthcare firm Medtronic Plc (NYSE: MDT), video game stock Take-Two Interactive Software Inc (NASDAQ:TTWO), and biotech PTC Therapeutics, Inc. (NASDAQ:PTCT). Here's a quick roundup of today's bearish brokerage notes on shares of MDT, TTWO, and PTCT.

Wells Fargo Downgrades MDT Stock

Medtronic stock is down 2.9% to trade at $77.49, after Wells Fargo downgraded the healthcare name to "market perform" from "outperform." The stock also received at least four price-target cuts, including one to $83 from $91 at Stifel. The flurry of bearish analyst attention comes after Medtronic updated the impact of Hurricane Maria on its fiscal second-quarter results.

MDT stock has shed 13.6% since touching a record high of $89.72 on June 26, and the extended pullback has been guided by the shares' 30-day moving average. A continued slide could encourage more downgrades -- which may create additional headwinds for the shares. As of last Friday's close, 11 of the 18 brokerages covering MDT stock rated it a "buy" or "strong buy."

Overbought TTWO Stock Slips After Downgrade

Cowen and Company chimed in on video game stocks today, saying it can't justify a bullish note for the outperforming sector amid a crowded calendar for fall game releases and sky-high expectations. Take-Two Interactive Software was not spared, getting downgraded to "market perform" from "outperform."

TTWO stock, which is currently down 3.1% to trade at $103.91, touched a record high of $107.53 last Friday, and is still maintaining a 110% year-to-date gain. Considering the security's 14-day Relative Strength Index (RSI) closed Friday at 70 --- signaling the shares were "overbought" -- today's pullback may have been in the cards.

J.P. Morgan Securities Downgrades PTC Therapeutics Stock

J.P. Morgan Securities downgraded PTC Therapeutics to "underweight" from "neutral" and slashed its price target by $8 to $15, sending the biotech stock down 4.1% to trade at $18.83. Analysts cited a low probability of approval from the Food and Drug Administration (FDA) for the company's rare muscle disease treatment by the Tuesday, Oct. 24, deadline date. It's nevertheless been a stellar year for PTCT stock, which has tacked on over 72% year-to-date.
Options traders an the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) have had a healthier-than-usual appetite for puts over calls lately. PTCT stock sports a 10-day put/call volume ratio of 2.24 -- higher than 84% of comparable readings taken in the past year.


Target Effortless Triple-Digit Gains Every Sunday Evening For Life!

This is your chance to triple your profit potential on Sunday evenings, without spending all your free time watching the market.

On Sundays, as a Weekend Plus subscriber, you’ll get up to 6 trades every Sunday, each targeting gains of 200% or more.

Start targeting gains like the ones our subscribers have seen recently, including:

213.3% GAIN on AutoNation calls
100.0% GAIN on Monster Beverage calls
100.4% GAIN on Walgreens Boots Alliance puts
100.4% GAIN on ON Semiconductor calls
257.7% GAIN on Dell calls

101.0% GAIN on Apollo Global Management calls
103.6% GAIN on JP Morgan  Chase calls
105.3% GAIN on DraftKings calls
101.3% GAIN on Airbnb calls
203.0% GAIN on Shopify calls
102.0% GAIN on Cboe Global Markets calls
100.9% GAIN on Boeing calls
102.1% GAIN on Microsoft puts
102.3% GAIN on First Solar calls
101.5% GAIN on PulteGroup calls
101.0% GAIN on Apple calls
209.4% GAIN on NXP Semiconductors calls
100.8% GAIN on Uber Technologies calls
100.4% GAIN on Academy Sports and Outdoors puts
102.2% GAIN on Trade Desk calls
100.8% GAIN on DoorDash calls
100.0% GAIN on Camping World Holdings puts
100.0% GAIN on Cboe Global Markets calls
100.2% GAIN on C3.ai calls
238.5% GAIN on Oracle calls



Rainmaker Ads CGI